CurrentEndo
Get Weekly

CurrentEndo coverage · page 37 of 55

Diabetes, Obesity and Metabolism

Briefs 1,441–1,480 of 2,200 CurrentEndo has covered from this journal, newest publication first

Latest from Diabetes, Obesity and Metabolism

All coverage, newest first

  1. Diabetes Obes Metab

    Relationship between weight‐adjusted‐waist index and all‐cause and cardiovascular mortality in individuals with type 2 diabetes

    Cohort studyT2D & other

  2. Diabetes Obes Metab

    Impact of baseline characteristics on the efficacy of once‐weekly subcutaneous semaglutide among participants with type 2 diabetes : A post hoc analysis of SUSTAIN China

    Secondary analysisT2D & other

  3. Diabetes Obes Metab

    Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants

    Randomized controlled trialObesity

  4. Diabetes Obes Metab

    Associations between cuprotosis‐related genes and the spectrum of metabolic dysfunction‐associated fatty liver disease: An exploratory study

    Diagnostic or prognostic studyLipids & liver

  5. Diabetes Obes Metab

    Detection of hypoglycaemia in type 1 diabetes through breath volatile organic compound profiling using gas chromatography–ion mobility spectrometry

    Diagnostic or prognostic studyT1D

  6. Diabetes Obes Metab

    Treatment trajectories for Danish individuals with type 2 diabetes in the era of emerging glucose‐lowering therapies

    Cohort studyT2D & other

  7. Diabetes Obes Metab

    The association of glycaemic risk factors and diabetes duration with risk of heart failure in people with type 2 diabetes: A systematic review and meta‐analysis

    Meta-analysisT2D & other

  8. Diabetes Obes Metab

    Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: real‐world analysis

    Cohort studyTechnology

  9. Diabetes Obes Metab

    A meta‐analysis of randomized controlled studies examining the effects of sodium‐glucose co‐transporter‐2 inhibitors on peripheral artery disease and risk of amputations

    Meta-analysisT2D & other

  10. Diabetes Obes Metab

    Ultra‐processed foods cause weight gain and increased energy intake associated with reduced chewing frequency: A randomized, open‐label, crossover study

    Randomized controlled trialObesity

  11. Diabetes Obes Metab

    The impact of overweight and obesity on health outcomes in the United States from 1990 to 2021

    Secondary analysisObesity

  12. Diabetes Obes Metab

    Prevalence of complications and co‐morbidities in males and females with obesity: Real‐world insights from claims data analysis

    Cross-sectional studyObesity

  13. Diabetes Obes Metab

    Lipids and apolipoproteins and the risk of vascular disease and mortality outcomes in women and men with type 2 diabetes in the ADVANCE study

    Secondary analysisT2D & other

  14. Diabetes Obes Metab

    Sodium‐glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real‐world patients with type 2 diabetes

    Cohort studyT2D & other

  15. Diabetes Obes Metab

    Glyburide use is associated with a greater likelihood of mortality or rehospitalization after acute coronary syndrome compared to gliclazide use in adults with type 2 diabetes: A cohort study

    Cohort studyT2D & other

  16. Diabetes Obes Metab

    Real‐world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus

    Cohort studyT2D & other

  17. Diabetes Obes Metab

    Performance of the MiniMed 780 G system on mitigating menstrual cycle‐dependent glycaemic variability

    Research articleT1D

  18. Diabetes Obes Metab

    Association of sodium‐glucose cotransporter 2 inhibitors with risk of incident dementia and all‐cause mortality in older patients with type 2 diabetes: A retrospective cohort study using the TriNetX US collaborative networks

    Cohort studyT2D & other

  19. Diabetes Obes Metab

    Semaglutide use in people with obesity and type 2 diabetes from real‐world utilization data: An analysis of the All of US Program

    Cohort studyObesity

  20. Diabetes Obes Metab

    Time‐in‐range derived from self‐measured blood glucose in people with type 2 diabetes advancing to iGlarLixi : A participant‐level pooled analysis of three phase 3 LixiLan randomized controlled trials

    Meta-analysisT2D & other

  21. Diabetes Obes Metab

    Association of N‐terminal pro‐B natriuretic peptide with all‐cause mortality and cardiovascular mortality in obese and non‐obese populations and the development of a machine learning prediction model: National Health and Nutrition Examination Survey (NHANES) 1999–2004

    Cohort studyObesity

  22. Diabetes Obes Metab

    Evaluating remission of type 2 diabetes using a metabolic intervention including fixed‐ratio insulin degludec and liraglutide: A randomized controlled trial

    Randomized controlled trialT2D & other

  23. Diabetes Obes Metab

    Causal relationship between key genes and metabolic dysfunction‐associated fatty liver disease risk mediated by immune cells: A Mendelian randomization and mediation analysis

    Research articleLipids & liver

  24. Diabetes Obes Metab

    Birthweight influences liver structure, function and disease risk: Evidence of a causal association

    Research articleLipids & liver

  25. Diabetes Obes Metab

    Fracture risk revisited: Bone mineral density T‐score and fracture risk in type 2 diabetes

    Cohort studyBone & mineral

  26. Diabetes Obes Metab

    Mediating role of inflammatory biomarkers in the causal effect of body composition on glycaemic traits and type 2 diabetes

    Cohort studyT2D & other

  27. Diabetes Obes Metab

    Generating real‐world evidence on diabetes technology using the CareLink Personal data management system

    Diagnostic or prognostic studyT1D

  28. Diabetes Obes Metab

    Glycated haemoglobin variability and risk of renal function decline in type 2 diabetes mellitus: An updated systematic review and meta‐analysis

    Meta-analysisT2D & other

  29. Diabetes Obes Metab

    Non‐invasive metabolic biomarkers in initial cognitive impairment in patients with diabetes: A systematic review and meta‐analysis

    Meta-analysisComplications

  30. Diabetes Obes Metab

    Utilization and cost of non‐insulin glucose‐lowering drugs in Australia from 2013 to 2023

    Cohort studyT2D & other

  31. Diabetes Obes Metab

    Effects of ertugliflozin on uric acid and gout‐related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV

    Secondary analysisT2D & other

  32. Diabetes Obes Metab

    Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction‐associated steatotic liver disease: A prospective, multicentre, observational study

    Cohort studyT2D & other

  33. Diabetes Obes Metab

    The effectiveness and sustainability of health outcomes from a holistic digital weight‐loss service with concomitant initiation of tirzepatide: A pragmatic randomized controlled trial in the UK

    Randomized controlled trialObesity

  34. Diabetes Obes Metab

    Efficacy and safety of dapagliflozin add‐on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled study

    Randomized controlled trialT2D & other

  35. Diabetes Obes Metab

    Glucose‐lowering medicines use before and after entry into long‐term care facilities

    Cohort studyT2D & other

  36. Diabetes Obes Metab

    The association of type 2 diabetes‐related characteristics with fracture risk at different sites

    Cohort studyT2D & other

  37. Diabetes Obes Metab

    The use of composite endpoints in cardiovascular outcome trials for diabetes: A review of 22 randomized clinical trials published since 2008

    Meta-analysisT2D & other

  38. Diabetes Obes Metab

    Patients with type 1 diabetes are at elevated risk of developing new hypertension, chronic kidney disease and diabetic ketoacidosis after COVID ‐19: Up to 40 months’ follow‐up

    Cohort studyT1D

  39. Diabetes Obes Metab

    Updating and calibrating the Real‐World Progression In Diabetes (RAPIDS) model in a non‐Veterans Affairs population

    Diagnostic or prognostic studyT2D & other

  40. Diabetes Obes Metab

    Adherence to glucagon‐like peptide ‐1 receptor agonist treatment in type 2 diabetes mellitus: A nationwide registry study

    Cohort studyT2D & other

All 2,200 Briefs in ExploreShowing Briefs 1,441–1,480 of 2,200, newest first